Cancer gene therapy is an innovative treatment approach that involves modifying or manipulating the genetic material within a patient's cells to fight cancer. This method aims to correct or replace defective genes, activate tumor-suppressing genes, or introduce new genes that can enhance the immune system’s ability to target and destroy cancer cells. By directly altering the genetic makeup of cells, gene therapy offers the potential to treat cancer more precisely, reducing side effects commonly associated with traditional therapies like chemotherapy and radiation. It includes techniques like gene transfer, gene editing (such as CRISPR-Cas9), and the use of viral vectors to deliver therapeutic genes. 

The rising prevalence of cancer is driving demand for innovative therapies, with WHO data indicating cancer affects 1 in 5 people globally. Significant market growth is fueled by advancements in research, product technologies, and increased R&D investment by key players. For example, in April 2023, a new gene editing method using cell-penetrating peptides marked a breakthrough in cell and gene therapies. Strategic collaborations, such as the August 2023 partnership between Astellas and Poseida Therapeutics, are accelerating the development of advanced cancer cell therapies. Additionally, the market is expanding due to rising cases of lifestyle diseases like diabetes and obesity, increased healthcare spending, a growing elderly population, and higher demand for diagnostics and preventative healthcare solutions. 

The cancer gene therapy market faces several critical challenges that could hinder its widespread adoption and development. One major barrier is the high cost of research, development, and treatment, making these therapies inaccessible for many patients and putting pressure on healthcare systems. Additionally, complex regulatory pathways and lengthy approval processes can delay the entry of new therapies into the market. Scientific hurdles, such as ensuring targeted and efficient delivery of therapeutic genes without affecting healthy cells, also pose significant obstacles. Safety concerns, including potential immune reactions and long-term effects of gene modifications, further complicate clinical applications. 

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals Inc.

By Product Therapy: Based on the Product Therapy, Global Cancer Gene Therapy Market is segmented as; Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer.

By End Use: Based on the End Use, Global Cancer Gene Therapy Market is segmented as; Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.